Shares of Anacor Pharmaceuticals (NASDAQ: ANAC) jumped 26% one day, and 30% the next, with an even bigger catalyst on the horizon. What is driving these explosive share price surges? In the video below, Fool analyst David Williamson discusses one phase 2 trial that has the markets excited, and tells us why the results from its upcoming phase 3 trial for this candidate pipeline drug could be even bigger.
This pharmaceutical company is unstoppable.
About the Author
The Motley Fool's Healthcare Analyst, I specialize in Pharma, Biotech, and how the ACA (Obamacare) is changing the business of healthcare in America. Follow me on Twitter for breaking stock news, policy thoughts, and misc musings...
Follow @motleydavid